sebaceous adenocarcinoma: An adenocarcinoma with sebaceous differentiation. It presents as a painless mass and it may be multifocal. It grows in the ocular adnexae and in the skin of head and neck, trunk, genitals, and extremities. It is characterized by the presence of malignant cells with multivesicular and clear cytoplasm. It may recur and metastasize.
Benign neoplasm: Endocrine gland, other/unspecified
DOID EFO Endpoint Browser PheWeb
CD2_BENIGN_ENDOCRINE_NOS
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
473681 |
1. Apply sex-specific ruleNone |
473681 |
2. Check conditionsNone |
473681 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
107 |
4. Check minimum number of eventsNone |
107 |
5. Include endpointsNone |
107 |
6. Filter based on genotype QC (FinnGen only) |
105 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2
Similar endpoints
↥List of similar endpoints to
Benign neoplasm: Endocrine gland, other/unspecified
based on the number of shared cases.
Similar with more cases:
- Benign neoplasm: Endocrine gland, other/unspecified
- Benign neoplasm of other and unspecified endocrine glands
- Benign neoplasm of other and unspecified endocrine glands
- Benign neoplasms
- Benign neoplasms
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 999 | 722 | 274 |
| Only index persons | 839 | 614 | 225 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.01 |
| Only index persons | 0.02 | 0.02 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 49.11 | 47.26 | 53.96 |
| Only index persons | 47.98 | 46.50 | 52.02 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 105 | 75 | 30 |
| Unadjusted period prevalence (%) | 0.03 | 0.03 | 0.02 |
| Median age at first event (years) | 47.19 | 44.54 | 53.80 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
Mortality – FinRegistry
↥Association
Association between endpoint CD2_BENIGN_ENDOCRINE_NOS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CD2_BENIGN_ENDOCRINE_NOS | 1.767 [1.31, 2.38] | < 0.001 |
| Birth year | 0.994 [0.98, 1.0] | 0.159 |
During the follow-up period (1.1.1998 — 31.12.2019), 66 out of 342 females with CD2_BENIGN_ENDOCRINE_NOS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CD2_BENIGN_ENDOCRINE_NOS | 1.457 [1.0, 2.12] | 0.048 |
| Birth year | 0.986 [0.98, 1.0] | 0.005 |
During the follow-up period (1.1.1998 — 31.12.2019), 53 out of 174 males with CD2_BENIGN_ENDOCRINE_NOS died.
Mortality risk
Mortality risk for people of age
years, who have CD2_BENIGN_ENDOCRINE_NOS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.173% | 0.259% |
| 5 | 1.091% | 1.623% |
| 10 | 2.446% | 4.189% |
| 15 | 4.468% | 7.8% |
| 20 | 7.965% | 13.257% |
Relationships between endpoints
↥Index endpoint: CD2_BENIGN_ENDOCRINE_NOS – Benign neoplasm: Endocrine gland, other/unspecified
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
Extremity
rg [CI]
Extremity
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data